425
Participants
Start Date
November 8, 2016
Primary Completion Date
January 23, 2019
Study Completion Date
April 21, 2022
Nivolumab
Ipilimumab
Placebo
Local Institution - 0121, Pergamino
Local Institution - 0017, Sandton
Local Institution - 0065, Bergen
Local Institution - 0053, Yvoir
Local Institution, Port Elizabeth
Local Institution, Cape Town
Local Institution - 0023, Ghent
Local Institution - 0074, Sint-Niklaas
Local Institution - 0075, Marseille
Local Institution - 0040, A Coruña
Local Institution - 0006, Pittsburgh
Donald Guthrie Foundation, Sayre
Local Institution - 0041, San Sabastian Gipuzkoa
Local Institution, Milan
Local Institution - 0077, Madrid
Mission Hospital, Inc, Asheville
Local Institution - 0076, Marbella
Local Institution - 0015, Decatur
Local Institution - 0010, Atlanta
Local Institution - 0120, Bordeaux
Local Institution - 0007, Tampa
Local Institution - 0030, Rennes
Local Institution - 0062, Izmir
Local Institution - 0005, Louisville
Oncology Associated Of Western Kentucky, Paducah
Local Institution - 0070, Cleveland
Local Institution - 0103, Cincinnati
Ft. Wayne Med Onco-Hema Inc, Fort Wayne
Local Institution - 0042, Rochester
Local Institution - 0087, Chicago
Local Institution - 0073, Clermont-Ferrand
Local Institution - 0108, Oaxaca City
Local Institution - 0029, Lyon
Local Institution - 0102, Dallas
Local Institution - 0032, Amiens
Local Institution - 0119, Napoli
Los Angeles Cancer Network, Los Angeles
Ucla Department Of Medicine, Los Angeles
Local Institution - 0098, Redondo Beach
Local Institution - 0034, Duarte
Local Institution - 0089, Clichy
Local Institution - 0097, San Luis Obispo
Central Coast Med Oncology, Santa Maria
Local Institution - 0072, San Francisco
Local Institution - 0088, Villejuif
Local Institution - 0004, Sacramento
Local Institution - 0090, Mérida
Local Institution - 0107, Mérida
Local Institution - 0008, Portland
Local Institution - 0038, Seattle
Local Institution - 0031, Moscow
Local Institution - 0033, Craiova
Local Institution - 0092, Ryazan
Local Institution - 0054, Cluj-Napoca
Local Institution - 0060, Iași
Local Institution - 0059, Suceava
University of Arizona Cancer Center, Tucson
Local Institution - 0101, New Haven
Local Institution - 0001, Boston
Local Institution - 0071, Boston
Local Institution - 0111, Buenos Aires
Local Institution - 0046, Belo Horizonte
Local Institution - 0124, Ipatinga
Local Institution - 0047, Curitiba
Local Institution - 0125, Caxias do Sul
Local Institution - 0051, Ijuí
Local Institution - 0052, Porto Alegre
Local Institution - 0045, Barretos
Local Institution - 0123, Santo André
Local Institution - 0048, São José do Rio Preto
Local Institution, Rio de Janeiro
Local Institution - 0049, São Paulo
Local Institution - 0050, São Paulo
Local Institution - 0013, Edmonton
Local Institution - 0056, Ottawa
Local Institution - 0012, Toronto
Local Institution - 0016, Montreal
Local Institution - 0014, Québec
Local Institution - 0115, Santiago
Local Institution - 0026, Dublin
Local Institution - 0022, Brno
Local Institution - 0020, Hradec Králové
Local Institution - 0021, Olomouc
Local Institution - 0069, Helsinki
Local Institution - 0079, Nice
Local Institution - 0068, Amsterdam
Local Institution - 0028, Amsterdam
Local Institution - 0027, Groningen
Local Institution - 0064, Oslo
Local Institution - 0055, Bucharest
Local Institution, Pretoria
Local Institution - 0116, Barcelona
Local Institution - 0039, Barcelona
Local Institution - 0067, Gothenburg
Local Institution - 0037, Lund
Local Institution - 0035, Stockholm
Local Institution - 0063, Adana
Local Institution - 0066, Antalya
Local Institution - 0110, Aberdeen
Local Institution - 0086, London
Local Institution - 0083, Metropolitan Borough of Wirral
Local Institution - 0081, Sutton
Local Institution - 0114, Cardiff
Local Institution - 0084, Glasgow
Local Institution - 0082, Newcastle upon Tyne
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY